BioSpace News Archive

Vascular Therapies, a privately held biotechnology company is developing Sirogen™, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels.

The University of Utah, ARUP Laboratories, and Techcyte Inc. announced that they have formed a partnership to develop NanoSpot.AI, a less than five-minute, easy-to-administer SARS-CoV-2 antibody test.

Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, and B2S Life Sciences, a biotherapeutic enablement company advancing improved analytical methods and outcomes for developers of biotherapeutic drugs and diagnostics, shared key ways to navigate the immunogenicity and biomarker requirements for clinical trials via webinar.

James Lanthier, CEO of Mindset, commented, “N,N-dimethyltryptamine (DMT) & 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) are potent, short-acting psychedelic drugs that produce strong hallucinogenic effects.

The company’s aim is to obtain regulatory approval and clinical laboratory licenses to be fully operational in early 2022 and start offering its metabolomics biomarker panel for early lung cancer detection to physicians initially across the Province of Quebec.

The study was recently published in the Scientific Journal titled “Cancers”.

As we continue to roll out COVID-19 vaccines across the country, the Government of Canada is committed to addressing and reducing barriers to vaccination.

Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval, the electronic filing system for the disclosure documents of issuers across Canada at www.SEDAR.com.

ALS patients showed a diminished disease progression based on analysis of functional endpoints. The study was recently published in the journal Brain.

In 58 patients diagnosed with acute adenoviral conjunctivitis, OKG-0301 was safe and demonstrated an effective, dose-dependent anti-viral response.